BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial. World J Gastroenterol 2004; 10(24): 3634-3638 [PMID: 15534920 DOI: 10.3748/wjg.v10.i24.3634]
URL: https://www.wjgnet.com/1007-9327/full/v10/i24/3634.htm
Number Citing Articles
1
Ajit S. Narang, Sailesh Varia. Role of tumor vascular architecture in drug deliveryAdvanced Drug Delivery Reviews 2011; 63(8): 640 doi: 10.1016/j.addr.2011.04.002
2
Yalei Zhang, Ling Qian, Kun Chen, Sijia Gu, Zhiqiang Meng, Jia Wang, Ye Li, Peng Wang. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell studyMolecular Therapy 2024; 32(6): 2000 doi: 10.1016/j.ymthe.2024.04.029
3
Audrey Choi, Michael O’Leary, Yuman Fong, Nanhai Chen. From Benchtop to Bedside: A Review of Oncolytic VirotherapyBiomedicines 2016; 4(3): 18 doi: 10.3390/biomedicines4030018
4
Nasser Hashemi Goradel, Nasir Mohajel, Ziba Veisi Malekshahi, Samira Jahangiri, Masoud Najafi, Bagher Farhood, Keywan Mortezaee, Babak Negahdari, Arash Arashkia. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approachesJournal of Cellular Physiology 2019; 234(6): 8636 doi: 10.1002/jcp.27850
5
Biyun Cun, Xin Song, Renbing Jia, Xiaoping Zhao, Haibo Wang, Shengfang Ge, Xianqun Fan. Combination of oncolytic adenovirus and dacarbazine enhances antitumor ability against uveal melanoma cells via cell cycle blockCancer Biology & Therapy 2012; 13(2): 77 doi: 10.4161/cbt.13.2.18436
6
Changqing Su, Hui Cao, Shuping Tan, Yao Huang, Xiaoyuan Jia, Lixin Jiang, Kai Wang, Ying Chen, Ju Long, Xinyuan Liu, Mengchao Wu, Xiaobing Wu, Qijun Qian. Toxicology Profiles of a Novel p53-Armed Replication-Competent Oncolytic Adenovirus in Rodents, Felids, and Nonhuman PrimatesToxicological Sciences 2008; 106(1): 242 doi: 10.1093/toxsci/kfn168
7
Michael Phan, Margaret F. Watson, Tommy Alain, Jean-Simon Diallo. Oncolytic Viruses on Drugs: Achieving Higher Therapeutic EfficacyACS Infectious Diseases 2018; 4(10): 1448 doi: 10.1021/acsinfecdis.8b00144
8
Masayuki Kurooka, Yasufumi Kaneda. Inactivated Sendai Virus Particles Eradicate Tumors by Inducing Immune Responses through Blocking Regulatory T CellsCancer Research 2007; 67(1): 227 doi: 10.1158/0008-5472.CAN-06-1615
9
Chao Fang, Gaozhe Xiao, Taixia Wang, Li Song, Bo Peng, Bin Xu, Kun Zhang. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer ImmunotherapyResearch 2023; 6 doi: 10.34133/research.0108
10
Danni Lin, Yinan Shen, Tingbo Liang. Oncolytic virotherapy: basic principles, recent advances and future directionsSignal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01407-6
11
Noga Lipschitz, Brian R. Earl, Timothy P. Cripe, Ravi N. Samy. Oncolytic virotherapy: a potential therapeutic approach for cholesteatomaCurrent Opinion in Otolaryngology & Head & Neck Surgery 2020; 28(5): 281 doi: 10.1097/MOO.0000000000000651
12
Pei-Hsin Cheng, Stephen Wechman, Kelly McMasters, Heshan Zhou. Oncolytic Replication of E1b-Deleted AdenovirusesViruses 2015; 7(11): 5767 doi: 10.3390/v7112905
13
Lihong Wang, Louisa S Chard Dunmall, Zhenguo Cheng, Yaohe Wang. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatmentJournal for ImmunoTherapy of Cancer 2022; 10(5): e004167 doi: 10.1136/jitc-2021-004167
14
Ta-Chiang Liu, Evanthia Galanis, David Kirn. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progressNature Clinical Practice Oncology 2007; 4(2): 101 doi: 10.1038/ncponc0736
15
Patrycja J Lech, Stephen J Russell. Use of attenuated paramyxoviruses for cancer therapyExpert Review of Vaccines 2010; 9(11): 1275 doi: 10.1586/erv.10.124
16
Ding Wei, Jing Xu, Xin-Yuan Liu, Zhi-Nan Chen, Huijie Bian. Fighting Cancer with Viruses: Oncolytic Virus Therapy in ChinaHuman Gene Therapy 2018; 29(2): 151 doi: 10.1089/hum.2017.212
17
Richard Kolade Omole, Oluwaseyi Oluwatola, Millicent Tambari Akere, Joseph Eniafe, Elizabeth Oladoyin Agboluaje, Oluwafemi Bamidele Daramola, Yemisi Juliet Ayantunji, Temiloluwa Ifeoluwa Omotade, Nkem Torimiro, Modupe Stella Ayilara, Oluwole Isaac Adeyemi, Olubusola Sajanat Salinsile. Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapyFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1082797
18
M Shiina, M D Lacher, C Christian, W M Korn. RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenovirusesCancer Gene Therapy 2009; 16(11): 810 doi: 10.1038/cgt.2009.29
19
E. V. Melnikova, O. A. Rachinskaya, V. A. Merkulov. Advanced Therapy Medicines Based on Oncolytic Viruses (Part I: Development and Authorisation of Products in China)The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2021; 11(3): 148 doi: 10.30895/1991-2919-2021-11-148-159
20
Jonathan M. Goodwin, Anthony D. Schmitt, Christopher M. McGinn, Bryan C. Fuchs, Darshini Kuruppu, Kenneth K. Tanabe, Michael Lanuti. Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer ModelCancer Investigation 2012; 30(3): 243 doi: 10.3109/07357907.2012.654870
21
Palaniyandi Muthukutty, So Young Yoo. Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy PerspectiveViruses 2023; 15(8): 1645 doi: 10.3390/v15081645
22
Bryan Oronsky, Brian Gastman, Anthony P. Conley, Christopher Reid, Scott Caroen, Tony Reid. Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotCancers 2022; 14(19): 4701 doi: 10.3390/cancers14194701
23
K. Devaraja. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell CarcinomaPharmaceutical Medicine 2019; 33(4): 269 doi: 10.1007/s40290-019-00288-x
24
Stephen Wechman, Xiao-Mei Rao, Kelly McMasters, Heshan Zhou. Adenovirus with DNA Packaging Gene Mutations Increased Virus ReleaseViruses 2016; 8(12): 333 doi: 10.3390/v8120333
25
Su Shao, Peng-Fei Xu, Xiao-Ping Zhan. Effects of H101 on proliferation, migration, and apoptosis of gastric cancer cells and underlying mechanismsWorld Chinese Journal of Digestology 2022; 30(18): 803 doi: 10.11569/wcjd.v30.i18.803
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
26
Ramon Alemany. Cancer selective adenovirusesMolecular Aspects of Medicine 2007; 28(1): 42 doi: 10.1016/j.mam.2006.12.002
27
Mari Raki, Merja Särkioja, Renee A. Desmond, Dung-Tsa Chen, Ralf Bützow, Akseli Hemminki, Anna Kanerva. Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancerGynecologic Oncology 2008; 108(1): 166 doi: 10.1016/j.ygyno.2007.09.013
28
Pin-I Huang, Ju-Fang Chang, David H. Kirn, Ta-Chiang Liu. Targeted genetic and viral therapy for advanced head and neck cancersDrug Discovery Today 2009; 14(11-12): 570 doi: 10.1016/j.drudis.2009.03.008
29
JUNFEN MA, JIMIN ZHAO, JING LU, YANAN JIANG, HONGYAN YANG, PEI LI, MINGYAO ZHAO, KANGDONG LIU, ZIMING DONG. Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancerInternational Journal of Molecular Medicine 2012; 30(6): 1403 doi: 10.3892/ijmm.2012.1133
30
O. Hemminki, R. Immonen, J. Närväinen, A. Kipar, J. Paasonen, K.T. Jokivarsi, H. Yli‐Ollila, P. Soininen, K. Partanen, T. Joensuu, S. Parvianen, S.K. Pesonen, A. Koski, M. Vähä‐Koskela, V. Cerullo, S. Pesonen, O.H. Gröhn, A. Hemminki. In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus respondersInternational Journal of Cancer 2014; 134(12): 2878 doi: 10.1002/ijc.28615
31
Talal Alzahrani, Raluca Eftimie, Dumitru Trucu. Multiscale modelling of cancer response to oncolytic viral therapyMathematical Biosciences 2019; 310: 76 doi: 10.1016/j.mbs.2018.12.018
32
Chen Liu, Bin Sun, Ni An, Weifeng Tan, Lu Cao, Xiangji Luo, Yong Yu, Feiling Feng, Bin Li, Mengchao Wu, Changqing Su, Xiaoqing Jiang. Inhibitory effect of Survivin promoter‐regulated oncolytic adenovirus carrying P53 gene against gallbladder cancerMolecular Oncology 2011; 5(6): 545 doi: 10.1016/j.molonc.2011.10.001
33
Kyle G. Potts, Mary M. Hitt, Ronald B. Moore. Oncolytic Viruses in the Treatment of Bladder CancerAdvances in Urology 2012; 2012: 1 doi: 10.1155/2012/404581
34
Soo-Hyun Kim, Crispin R Dass. p53-targeted cancer pharmacotherapy: move towards small molecule compoundsJournal of Pharmacy and Pharmacology 2011; 63(5): 603 doi: 10.1111/j.2042-7158.2010.01248.x
35
Chao-Bin He, Xiang-Ming Lao, Xiao-Jun Lin. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram studyChinese Journal of Cancer 2017; 36(1) doi: 10.1186/s40880-017-0227-2
36
Xiao-jun Lin, Qi-jiong Li, Xiang-ming Lao, Han Yang, Sheng-ping Li. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1715-x
37
Daniel Cervantes-García;, Rocío Ortiz-López;, Netzahualcoyotl Mayek-Pérez;, Augusto Rojas-Martínez;. Oncolytic virotherapyAnnals of Hepatology 2008; 7(1): 34 doi: 10.1016/S1665-2681(19)31885-X
38
Xiangxing Liu, Jiaojiao Zhang, Keqing Feng, Simin Wang, Liming Chen, Suping Niu, Qian Lu, Yi Fang. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysisFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1023533
39
Gerard V. Walls, Manuel C. Lemos, Mahsa Javid, Miriam Bazan-Peregrino, Jeshmi Jeyabalan, Anita A.C. Reed, Brian Harding, Damian J. Tyler, Daniel J. Stuckey, Sian Piret, Paul T. Christie, Olaf Ansorge, Kieran Clarke, Len Seymour, Rajesh V. Thakker. MEN1 Gene Replacement Therapy Reduces Proliferation Rates in a Mouse Model of Pituitary AdenomasCancer Research 2012; 72(19): 5060 doi: 10.1158/0008-5472.CAN-12-1821
40
Megan Grundy, Constantin Coussios, Robert Carlisle. Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancerExpert Opinion on Drug Delivery 2016; 13(7): 999 doi: 10.1517/17425247.2016.1167036
41
Mari Raki, Daniel T. Rein, Anna Kanerva, Akseli Hemminki. Gene Transfer Approaches for Gynecological DiseasesMolecular Therapy 2006; 14(2): 154 doi: 10.1016/j.ymthe.2006.02.019
42
Tanja Hakkarainen, Maria Rajecki, Mirkka Sarparanta, Mikko Tenhunen, Anu J. Airaksinen, Renée A. Desmond, Kalevi Kairemo, Akseli Hemminki. Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide SymporterClinical Cancer Research 2009; 15(17): 5396 doi: 10.1158/1078-0432.CCR-08-2571
43
Karoly Toth, William S. M. Wold. Increasing the Efficacy of Oncolytic Adenovirus VectorsViruses 2010; 2(9): 1844 doi: 10.3390/v2091844
44
Alexander Baker, Carmen Aguirre-Hernández, Gunnel Halldén, Alan Parker. Designer Oncolytic Adenovirus: Coming of AgeCancers 2018; 10(6): 201 doi: 10.3390/cancers10060201
45
Kelley A. Parato, Donna Senger, Peter A. J. Forsyth, John C. Bell. Recent progress in the battle between oncolytic viruses and tumoursNature Reviews Cancer 2005; 5(12): 965 doi: 10.1038/nrc1750
46
Christopher Y Woo, Takuya Osada, Timothy M Clay, H Kim Lyerly, Michael A Morse. Recent clinical progress in virus-based therapies for cancerExpert Opinion on Biological Therapy 2006; 6(11): 1123 doi: 10.1517/14712598.6.11.1123
47
Ellen A. M. Schenk‐Braat, Marjolein M. K. B. van Mierlo, Gerard Wagemaker, Chris H. Bangma, Leonie C. M. Kaptein. An inventory of shedding data from clinical gene therapy trialsThe Journal of Gene Medicine 2007; 9(10): 910 doi: 10.1002/jgm.1096
48
Junfen Ma, Nan Li, Jimin Zhao, Jing Lu, Yanqiu Ma, Qinghua Zhu, Ziming Dong, Kangdong Liu, Liang Ming. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivoOncology Letters 2017; 13(6): 4868 doi: 10.3892/ol.2017.6069
49
Alireza Shahryari, Marie Saghaeian Jazi, Saeed Mohammadi, Hadi Razavi Nikoo, Zahra Nazari, Elaheh Sadat Hosseini, Ingo Burtscher, Seyed Javad Mowla, Heiko Lickert. Development and Clinical Translation of Approved Gene Therapy Products for Genetic DisordersFrontiers in Genetics 2019; 10 doi: 10.3389/fgene.2019.00868
50
Adel H. Jebar, Richard G. Vile, Alan A. Melcher, Stephen Griffin, Peter J. Selby, Fiona Errington-Mais. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinomaJournal of General Virology 2015; 96(7): 1533 doi: 10.1099/vir.0.000098
51
Shruthi Naik, Stephen J Russell. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathwaysExpert Opinion on Biological Therapy 2009; 9(9): 1163 doi: 10.1517/14712590903170653
52
Niloofar Kiaheyrati, Abouzar Babaei, Reza Ranji, Ensiyeh Bahadoran, Shiva Taheri, Zahra Farokhpour. Cancer therapy with the viral and bacterial pathogens: The past enemies can be considered the present alliesLife Sciences 2024; 349: 122734 doi: 10.1016/j.lfs.2024.122734
53
Otto Hemminki, Akseli Hemminki. Gene Therapy of Cancer2014; : 153 doi: 10.1016/B978-0-12-394295-1.00011-1
54
Amir Fakhari, J. Anand Subramony. Engineered in-situ depot-forming hydrogels for intratumoral drug deliveryJournal of Controlled Release 2015; 220: 465 doi: 10.1016/j.jconrel.2015.11.014
55
Masayuki KUROOKA, Yasufumi KANEDA. Anticancer Immunotherapy using Inactivated Sendai Virus ParticlesUirusu 2007; 57(1): 19 doi: 10.2222/jsv.57.19
56
Chaobin He, Yu Zhang, Xiaojun Lin. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk AnalysisJournal of Gastrointestinal Surgery 2018; 22(6): 989 doi: 10.1007/s11605-018-3703-3
57
Simone Mocellin, Carlo R. Rossi, Alba Brandes, Donato Nitti. Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approachesCancer Treatment Reviews 2006; 32(1): 9 doi: 10.1016/j.ctrv.2005.10.003
58
L. Yi, Z. Ning, L. Xu, Y. Shen, X. Zhu, W. Yu, J. Xie, Z. Meng. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot studyESMO Open 2024; 9(2): 102239 doi: 10.1016/j.esmoop.2024.102239
59
Man Yao, Simo Cheng, Xiaofeng Zhai, Hetong Zhao, Jing Hong, Xiaoyan Li, Yongbin Meng, Wei Chen, Ye Liu. Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching AnalysisApplied Bionics and Biomechanics 2022; 2022: 1 doi: 10.1155/2022/9084852
60
Yalei Zhang, Ling Qian, Kun Chen, Sijia Gu, Jia Wang, Zhiqiang Meng, Ye Li, Peng Wang. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune responseMolecular Therapy - Oncolytics 2022; 25: 31 doi: 10.1016/j.omto.2022.03.003
61
Dörthe Masemann, Yvonne Boergeling, Stephan Ludwig. Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapyBiological Chemistry 2017; 398(8): 891 doi: 10.1515/hsz-2017-0103
62
Sufi Mary Thomas, Jennifer Rubin Grandis. The Current State of Head and Neck Cancer Gene TherapyHuman Gene Therapy 2009; 20(12): 1565 doi: 10.1089/hum.2009.163
63
Ngoc Kim Phan. Biological therapy: a new age of cancer treatmentBiomedical Research and Therapy 2014; 1(2) doi: 10.7603/s40730-014-0006-5
64
Maria Eugenia Davola, Karen Louise Mossman. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?OncoImmunology 2019; 8(6): e1581528 doi: 10.1080/2162402X.2019.1596006
65
Stephen Wechman, Xiao-Mei Rao, Pei-Hsin Cheng, Jorge Gomez-Gutierrez, Kelly McMasters, H. Zhou. Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer SelectionViruses 2016; 8(6): 167 doi: 10.3390/v8060167
66
Menghan Gao, Erik Yngve, Di Yu, Chuan Jin. A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus ProductsFrontiers in Molecular Biosciences 2022; 9 doi: 10.3389/fmolb.2022.883249
67
Xiaoyu Zhang, Tianyi Ding, Fan Yang, Haowen Xu, Jixing Zhang, Yiran Bai, Yibing Shi, Jiaqi Yang, Chaoqun Chen, He Zhang. Induced dual-target rebalance simultaneously enhances efficient therapeutical efficacy in tumorsCell Death Discovery 2024; 10(1) doi: 10.1038/s41420-024-02018-y
68
Qiong Lin, Deng-Gao Wang, Zhu-Qin Zhang, De-Pei Liu. Applications of Virus Vector–Mediated Gene Therapy in ChinaHuman Gene Therapy 2018; 29(2): 98 doi: 10.1089/hum.2017.238
69
Christos Fountzilas, Sukeshi Patel, Devalingam Mahalingam. Review: Oncolytic virotherapy, updates and future directionsOncotarget 2017; 8(60): 102617 doi: 10.18632/oncotarget.18309
70
Ran Zhang, Yanxin Cui, Xin Guan, Xiangjun Jiang. A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort StudyFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.752504
71
Yuguo Zhang, Musa Gabere, Mika A. Taylor, Camila C. Simoes, Chelsae Dumbauld, Oumar Barro, Mulu Z. Tesfay, Alicia L. Graham, Khandoker Usran Ferdous, Alena V. Savenka, Jean Christopher Chamcheu, Charity L. Washam, Duah Alkam, Allen Gies, Stephanie D. Byrum, Matteo Conti, Steven R. Post, Thomas Kelly, Mitesh J. Borad, Martin J. Cannon, Alexei Basnakian, Bolni M. Nagalo. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapyFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1042250
72
Daniel T. Rein, Anne Volkmer, Gerd Bauerschmitz, Ines M. Beyer, Wolfgang Janni, Markus C. Fleisch, Anne Kathrin Welter, Dirk Bauerschlag, Thomas Schöndorf, Martina Breidenbach. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancerJournal of Cancer Research and Clinical Oncology 2012; 138(4): 603 doi: 10.1007/s00432-011-1135-5
73
J P Hughes, G Alusi, Y Wang. Viral gene therapy for head and neck cancerThe Journal of Laryngology & Otology 2015; 129(4): 314 doi: 10.1017/S0022215114003247
74
Nasser Hashemi Goradel, Arezoo Alizadeh, Shahnaz Hosseinzadeh, Mitra Taghipour, Zeinab Ghesmati, Arash Arashkia, Babak Negahdari. Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic VirusesFuture Oncology 2022; 18(2): 245 doi: 10.2217/fon-2021-0802
75
Caihong Chen, Haiyan Fang, Yumei Rao, Peng Wu, Yang He, Ding Ma, Qinglei Gao. Preliminary evaluation of safety of conditionally replication adenovirus M4Journal of Huazhong University of Science and Technology [Medical Sciences] 2012; 32(6): 893 doi: 10.1007/s11596-012-1054-y
76
Karoly Toth, Debanjan Dhar, William SM Wold. Oncolytic (replication-competent) adenoviruses as anticancer agentsExpert Opinion on Biological Therapy 2010; 10(3): 353 doi: 10.1517/14712590903559822
77
Joshua Del Papa, Robin Parks. Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer AgentsViruses 2017; 9(1): 13 doi: 10.3390/v9010013
78
Deepak Babu, Amit Ranjan. Understanding Cancer2022; : 237 doi: 10.1016/B978-0-323-99883-3.00018-4
79
Behnaz Taheri, Zeinab Zarei-Behjani, Abouzar Babaei, Fatemeh Matin Moradkhan. Extracellular Vesicles: a Trojan Horse Delivery Method for Systemic Administration of Oncolytic VirusesRegenerative Engineering and Translational Medicine 2023; 9(4): 447 doi: 10.1007/s40883-023-00295-0
80
Xiao Yin Ma, Brett D. Hill, Trang Hoang, Fei Wen. Virus-inspired strategies for cancer therapySeminars in Cancer Biology 2022; 86: 1143 doi: 10.1016/j.semcancer.2021.06.021
81
Lizhi Li, Shixin Liu, Duoduo Han, Bin Tang, Jian Ma. Delivery and Biosafety of Oncolytic VirotherapyFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00475